Regentis Biomaterials Ltd. (RGNT)
| Market Cap | 37.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -333,000 |
| Shares Out | 5.18M |
| EPS (ttm) | -2.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 262 |
| Open | 7.20 |
| Previous Close | 7.50 |
| Day's Range | 7.20 - 7.20 |
| 52-Week Range | 6.96 - 7.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About RGNT
Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions in the United States. The company offers orthopedic treatments using Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. It offers Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylat... [Read more]
News
U.S. IPO Weekly Recap: December Kicks Off With 3 Notable Launches In A Week With 7 SPACs
The US IPO market entered the final stretch of the year with a few small listings, a wave of SPACs, and three notable deal launches on the calendar for the week ahead. With markets recovering from a r...
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering
Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative ...
Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering
Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative ...
Israeli hydrogel implant developer Regentis Biomaterials files and sets terms for a $10 million US IPO
Regentis Biomaterials, an Israeli regenerative medicine company developing orthopedic hydrogel implants, filed on Tuesday with the SEC to raise up to $10 million in an initial public offering.
Regentis Biomaterials IPO Registration Document (F-1)
Regentis Biomaterials has filed to go public with an IPO on the NASDAQ.